A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

被引：0
|
作者：
J E Ward
T Karrison
G Chatta
M Hussain
D Shevrin
R Z Szmulewitz
P H O'Donnell
W M Stadler
E M Posadas
机构：
[1] Section of Hematology/Oncology,Department of Medicine
[2] University of Chicago,Division of Hematology/Oncology, Department of Medicine
[3] University of Pittsburgh,Department of Internal Medicine
[4] University of Michigan,undefined
[5] Northshore University Health System,undefined
[6] Samuel Oschin Comprehensive Cancer Institute,undefined
[7] Cedars-Sinai Medical Center,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2012年 / 15卷
关键词：
intermittent androgen suppression; tyrosine kinase inhibitors; pazopanib randomized consortium trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 92
页数：5
相关论文
共 50 条
  • [1] A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study
    Ward, J. E.
    Karrison, T.
    Chatta, G.
    Hussain, M.
    Shevrin, D.
    Szmulewitz, R. Z.
    O'Donnell, P. H.
    Stadler, W. M.
    Posadas, E. M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) : 87 - 92
  • [2] A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study
    Ward, J. E.
    Limvorasak, S.
    Karrison, T.
    Chatta, G. S.
    Hussain, M.
    Shevrin, D. H.
    Szmulewitz, R. Z.
    Stadler, W. M.
    Posadas, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [3] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Roth, K.
    Wang, Y.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 808 - 813
  • [4] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    T M Beer
    D C Smith
    A Hussain
    M Alonso
    J Wang
    M Giurescu
    K Roth
    Y Wang
    British Journal of Cancer, 2012, 107 : 808 - 813
  • [5] Saracatinib as a Metastasis Inhibitor in Metastatic Castration-Resistant Prostate Cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study
    Posadas, Edwin M.
    Ahmed, Rafi S.
    Karrison, Theodore
    Szmulewitz, Russell Z.
    O'Donnell, Peter H.
    Wade, James L., III
    Shen, James
    Gururajan, Murali
    Sievert, Margarit
    Stadler, Walter M.
    PROSTATE, 2016, 76 (03): : 286 - 293
  • [6] Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research
    Morris, Michael J.
    Basch, Ethan M.
    Wilding, George
    Hussain, Maha
    Carducci, Michael A.
    Higano, Celestia
    Kantoff, Philip
    Oh, William K.
    Small, Eric J.
    George, Daniel
    Mathew, Paul
    Beer, Tomaz M.
    Slovin, Susan F.
    Ryan, Charles
    Logothetis, Christopher
    Scher, Howard I.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 51 - 57
  • [7] Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Scher, H.
    Beer, T.
    Higano, C.
    Logothetis, C.
    Shelkey, J.
    Hung, D.
    Hirmand, M.
    Larson, S.
    Fleisher, M.
    Sawyers, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 51 - 52
  • [8] Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study
    Davis, NB
    Taber, DA
    Ansari, RH
    Ryan, CW
    George, C
    Vokes, EE
    Vogelzang, NJ
    Stadler, WM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 115 - 119
  • [9] Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862) Trial Results and Interleukin-6 Analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
    Bradley, Deborah
    Rathkopf, Dana
    Dunn, Rodney
    Stadler, Walter M.
    Liu, Glenn
    Smith, David C.
    Pili, Roberto
    Zwiebel, James
    Scher, Howard
    Hussain, Maha
    CANCER, 2009, 115 (23) : 5541 - 5549
  • [10] A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial
    Lin, J.
    Beer, T. M.
    Ryan, C. J.
    Mathew, P.
    Wilding, G.
    Morris, M.
    Callahan, J. A.
    Gordon, G.
    Reich, S.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345